🎥 Missed EULAR 2026? No problem! With high5immunology.TV, you can catch up on the most important congress highlights – concise, scientifically sound, and highly relevant for clinical practice. Explore the latest clinical trial data, key abstracts, and expert perspectives on rheumatoid arthritis, lupus, psoriatic arthritis, spondyloarthritis, and other immune-mediated diseases. Our international experts attended the congress in London and provide clear, practical insights into the most relevant developments in rheumatology and immunology. ▶️ Watch now, free of charge, on high5immunology.TV – exclusively for healthcare professionals. high5immunology.tv/rheumatol… #EULAR2026 #EULAR #Rheumatology #Immunology #AutoimmuneDiseases #ClinicalTrials #Lupus #JAKInhibitors #PrecisionMedicine #MedicalEducation #ImmunologyResearch #high5immunologyTV

🎥 Welcome to EULAR 2026 In this special message, @XBaraliakos Xenofon Baraliakos, MD, President of EULAR, invites you to explore the latest scientific highlights from this year's congress on high5immunology.TV. From key study results to expert analyses and congress abstracts, our platform brings together the most relevant developments in rheumatology and immunology – presented by leading international experts. The EULAR 2026 content is now available free of charge for healthcare professionals on high5immunology.TV. 👉 Watch now: high5immunology.tv/rheumatol… #EULAR2026 #EULAR #XenofonBaraliakos #Rheumatology #Immunology #AutoimmuneDiseases #ClinicalTrials #MedicalEducation #high5immunologyTV

🎥 Behind the scenes at EULAR 2026 in London! While the latest breakthroughs in rheumatology and immunology are being presented at the congress, our team is already hard at work behind the camera. Together with leading international experts, we are presenting the most exciting study results, key congress highlights, and their relevance for clinical practice. Stay tuned for concise congress summaries, expert perspectives, and the most important take-home messages from EULAR 2026. 📅 Available June 6th 2026, free of charge, on high5immunology.TV – exclusively for healthcare professionals. #EULAR2026 #EULAR #Rheumatology #Immunology #AutoimmuneDiseases #ClinicalTrials #PrecisionMedicine #MedicalEducation #ImmunologyResearch #high5immunologyTV

All high5oncologyTV ASCO 2026 reports are now available on demand. 🎥 Expert coverage of: • Breast Cancer • GU Oncology • Lung Cancer ✅ Free access ✅ On demand ✅ For healthcare professionals Watch now: high5oncology.tv/meeting-cov… #ASCO26 #Oncology #high5oncologyTV

The first reports from our high5oncologyTV ASCO 2026 coverage are now live. 🎥 Expert analysis on: • Breast Cancer • GU Cancers • Lung Cancer ✅ Free ✅ On demand ✅ Directly from Chicago Watch now and stay up to date with the latest ASCO 2026 data: high5oncology.tv/meeting-cov… #ASCO26 #Oncology #high5oncologyTV

The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC . A snapshot of what will shape LUNG oncology at #ASCO26 👇 🔹 HARMONI-6 — Ivonescimab chemo vs tislelizumab chemo in sqNSCLC (OS, Ph3) 🔹 LIBRETTO-432 — Adjuvant selpercatinib in RET NSCLC (EFS, Ph3) 🔹 WU-KONG28 — Sunvozertinib vs chemo in EGFR Ex20ins NSCLC (Ph3) 🔹 OPTITROP-LUNGO5 — Sac-TMT pembrolizumab in PD-L1 NSCLC (Ph3) 🔹 TRITON — Tremelimumab/durvalumab/chemo in STK11/KEAP1/KRAS-mut NSCLC 🔹 CROWN 7-year update — Lorlatinib vs crizotinib in ALK NSCLC 🔹 LORIN — Neoadjuvant lorlatinib in stage III ALK NSCLC 🔹 ACCELERET-LUNG — 1L pralsetinib in RET NSCLC 🔹 Silevertinib (BDTX-1535) — Non-classical EGFR-mut NSCLC 🔹 Concurrent CRT durvalumab in ES-SCLC (Phase III) Leads @HHorinouchi @UOzkerim @WeOncologists Senior Faculty @GlopesMd @StephenVLiu @peters_solange @CharuAggarwalMD @MartinReck2 @christine_lovly Participating AF @DrMirallas Pinging faculty @bmassutis @UmbertoMalapel1 @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo @Latinamd @JulienMazieres @TerriConneran @BRicciutiMD

The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer . A snapshot of what will shape GU oncology at #ASCO26 👇 1️⃣ LBA5007 — TALAPRO-3 Talazoparib enzalutamide vs placebo enzalutamide in mCSPC with HRR alterations 2️⃣ LBA1 — PROTEUS Perioperative apalutamide ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3) 3️⃣ 5001 — ENZAMET genomic analysis Decipher >0.85 to identify benefit from adding docetaxel to ADT enzalutamide 4️⃣ LBA4511 — KEYNOTE-564 ctDNA ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo 5️⃣ 4502 — RAMPART Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT) 6️⃣ 4500 — RADICAL (A031801) Radium-223 cabozantinib in RCC with bone metastases 7️⃣ 4507 — EV-302 long-term follow-up Enfortumab vedotin pembrolizumab vs chemotherapy in 1L LA/mUC 8️⃣ 4513 — AMBASSADOR (A031501) HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC 9️⃣ 4503 — SAKK 06/19 Perioperative intravesical rBCG chemo-IO strategy in MIBC (primary analysis) 🔟 4510 — KEYNOTE-905 HRQoL with perioperative enfortumab vedotin pembrolizumab in cisplatin-ineligible MIBC Leads @nataliagandur @scocmem @AmandaNizamMD @WeOncologists Senior Faculty @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin Pinging @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini

🚨 The OncoAlert #BreastCancer faculty’s TOP 10 abstracts for #ASCO26 — selected by our leads and finalized through a Delphi voting process with senior breast cancer experts. 1️⃣ 500 — OPTIMA Test-directed chemotherapy in high-risk ER /HER2- early BC 2️⃣ LBA1006 — PERSEVERA BC Giredestrant palbociclib vs letrozole palbociclib in 1L ER /HER2- LA/MBC 3️⃣ 507 — KEYNOTE-522 final analysis Perioperative pembrolizumab in high-risk early TNBC 4️⃣ LBA1007 — SERENA-6 1L camizestrant for emergent ESR1 mutations — final PFS2 5️⃣ 502 — LIDERA BC Giredestrant in ER /HER2- early BC by menopausal status 6️⃣ LBA1000 — ASCENT-04 SG pembrolizumab vs chemo pembrolizumab in 1L PD-L1 mTNBC 7️⃣ 501 — NATALEE biomarker analysis Baseline gene expression and adjuvant ribociclib benefit 8️⃣ LBA503 — SENOMAC Omission of axillary dissection: OS arm morbidity 9️⃣ 1001 — ASCENT-03 SG vs chemotherapy in 1L mTNBC — PFS2 🔟 LBA1003 Izalontamab brengitecan vs physician’s choice chemo in metastatic TNBC Leads🚨 @ElisaAgostinett @to_be_elizabeth @WeOncologists Senior Faculty @ErikaHamilton9 @E_de_Azambuja @matteolambe @DrSGraff @hoperugo @BianchiniGP Dr. Bidard @Icro_Meattini Participating AF @Lucarecco @GaiaGriguolo Ping Faculty @aftimosp @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel

🎥 Leading international IBD experts united at the 5 Nations in IBD Meeting in Toledo. A huge thank you to all specialists who joined high5immunologyTV to share their perspectives, clinical insights, and the latest developments in IBD care. Watch all expert interviews and meeting highlights free and on demand: high5immunology.tv/ibd/5-nat… @alearmuzzi @manu_barreiro @yzabanaa @AngelaVariola @EdoSavarino @HenitYanaiMD @Max_Fantini @HelenaTavaresdS @IborraMarisa @CalafatSard @PGetaid @GEDII_IBD @geteccu @IGIS_ibd @IGIBD1 #5NationsIBD #IBD #Gastroenterology #5N #MedicalEducation #CrohnsDisease #UlcerativeColitis #Immunology

The 5 Nations Meeting in IBD starts today in Toledo — and the #high5immunologyTV team is live on site to bring you the latest expert insights and highlights from the meeting. 🎥 Full coverage will be available free and on demand starting Monday, May 25. Stay tuned! #5NationsIBD #IBD #Gastroenterology #InflammatoryBowelDisease #MedicalEducation

Recent weeks have brought important momentum in oncology, including several FDA approvals across different tumor types. 👉 Swipe for a concise overview of current and clinically relevant developments! #Oncology #Hematology #ProstateCancer #OvarianCancer #MultipleMyeloma

Upgrade your clinical tool kit with the updated high5 breast cancer app: all information from diagnosis, therapy algorithm to management of adverse effects. Developed by leading experts in the field – free download for all HCPs. Download now for free: breastcancer.high5md.com #BreastCancer #Oncology #EvidenceBasedMedicine #DigitalHealth #oncology #high5md

Missed ASCO GU 2026? We’ve got you covered. If you couldn’t attend in person, you don’t have to miss out on the key insights: The highlights from ASCO GU 2026 are now available on demand and free of charge on high5oncologyTV. Concise, clinically relevant, and accessible anytime – exclusively for healthcare professionals. 👉 Register now for free and start watching: high5oncology.tv/meeting-cov… #ASCOGU2026 #GUOncology #Oncology #MedicalEducation #MedEd

ASCO GU 2026 – the latest data in just 100 seconds! Our on-site experts present the newest insights from ASCO GU 2026 – concise, clinically relevant, and straight to the point. Stay up to date in genitourinary oncology in no time – on demand and free of charge on high5oncologyTV. 👉 Register now and get the most important results in 100 seconds: high5oncology.tv/meeting-cov… #ASCOGU2026 #GUOncology #Oncology #MedicalEducation #MedEd

⏱️ ASCO GU 2026 is just around the corner! Stay tuned for exclusive congress highlights and expert discussions – bringing you the latest insights directly from the meeting. On high5oncologyTV, you’ll be close to the most important new developments in genitourinary oncology. 👉 Register now for free and don’t miss out! high5oncology.tv/meeting-cov… #ASCOGU2026 #GUOncology #Oncology #MedicalEducation #Healthcare #MedEd

ECCO 2026 has come to an end – but the insights and discussions continue. On our website, you can now explore our full coverage, including exclusive expert videos, key takeaways, and in-depth analyses. Don’t miss the opportunity to catch up on the highlights! A special thank you to all the experts for the excellent collaboration and for the engaging and lively discussions captured in our videos. 🖥️ Visit our website high5immunology.TV and watch the content now! #ECCO2026 #MedEd #IBD #ColitisUlcerosa #CrohnsDisease

Couldn’t join ECCO 2026 in person? We’ve got you covered.  Our international experts discussed on how pathway-targeted therapies may reshape treatment strategies, how precision medicine is evolving towards more dynamic, data-driven decision-making, and how earlier intervention concepts and anti-fibrotic strategies could impact long-term disease control. 🔎 Watch the highlights now on high5immunology.TV! #ECCO2026 #IBD #Immunology #PrecisionMedicine #MedicalEducation

Our content from the ECCO Congress 2026 in Stockholm is now available! Explore concise summaries, the latest study data and practical expert insights from IBD. 💻 Watch now for free on high5immunology.TV

🗓️ Only a few days to go until #ECCO2026! Look forward to concise 100-second video updates and expert discussions covering the latest advances in IBD management — evidence-based, clinically relevant and to the point. Register for free at high5immunology.tv to stay ahead and make sure you don’t miss any highlights! #ECCO #IBD #Gastroenterology #Immunology #MedEd